Literature DB >> 17284639

Metabolic syndrome: a solution in search of a problem.

Ele Ferrannini1.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17284639     DOI: 10.1210/jc.2006-0944

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  24 in total

1.  Do insulinotropic glucose-lowering drugs do more harm than good? The hypersecretion hypothesis revisited.

Authors:  I Rustenbeck; S Baltrusch; M Tiedge
Journal:  Diabetologia       Date:  2010-07-01       Impact factor: 10.122

2.  Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?

Authors:  Matthew R Smith; A James O'Malley; Nancy L Keating
Journal:  BJU Int       Date:  2008-06       Impact factor: 5.588

3.  The metabolic syndrome: what's in a name?

Authors:  Glenn Matfin
Journal:  Ther Adv Endocrinol Metab       Date:  2010-04       Impact factor: 3.565

4.  Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

Authors:  Matthew R Smith; Hang Lee; Francis McGovern; Mary Anne Fallon; Melissa Goode; Anthony L Zietman; Joel S Finkelstein
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

5.  Intracellular molecular effects of insulin resistance in patients with metabolic syndrome.

Authors:  Evasio Pasini; Vincenzo Flati; Silvia Paiardi; Damiano Rizzoni; Enzo Porteri; Roberto Aquilani; Deodato Assanelli; Giovanni Corsetti; Silvia Speca; Rita Rezzani; Carolina De Ciuceis; Enrico Agabiti-Rosei
Journal:  Cardiovasc Diabetol       Date:  2010-09-01       Impact factor: 9.951

Review 6.  Metabolic complications of androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

7.  Silencing mitogen-activated protein 4 kinase 4 (MAP4K4) protects beta cells from tumor necrosis factor-alpha-induced decrease of IRS-2 and inhibition of glucose-stimulated insulin secretion.

Authors:  Karim Bouzakri; Pascale Ribaux; Philippe A Halban
Journal:  J Biol Chem       Date:  2009-08-18       Impact factor: 5.157

Review 8.  Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.

Authors:  Matthew R Smith
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

9.  Impact of the metabolic syndrome and its individual components on risk and severity of coronary heart disease.

Authors:  Yifei Zhang; Jie Hong; Weiqiong Gu; Minghui Gui; Ying Chen; Yu Zhang; Zhenni Chi; Weiqing Wang; Xiaoying Li; Guang Ning
Journal:  Endocrine       Date:  2009-07-18       Impact factor: 3.633

10.  Positive association between increased popliteal artery vessel wall thickness and generalized osteoarthritis: is OA also part of the metabolic syndrome?

Authors:  Peter R Kornaat; Ruby Sharma; Rob J van der Geest; Hildo J Lamb; Margreet Kloppenburg; Marie-Pierre Hellio le Graverand; Johan L Bloem; Iain Watt
Journal:  Skeletal Radiol       Date:  2009-07-03       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.